新诊断类风湿关节炎短期桥接治疗后成功停用口服糖皮质激素
基于ARCTIC试验中227例新诊断RA患者,初始甲氨蝶呤单药联合泼尼松龙桥接治疗(7周内从15mg减至0)。7周后84%成功停用泼尼松龙,24个月内达95%,中位使用天数55天,支持短期桥接后减停可行。
要点
- 新诊断RA患者7周桥接治疗后84%成功停用泼尼松龙。
- 24个月内95%患者停用,中位使用天数仅55天。
- 仅22%患者连续使用泼尼松龙≥3个月。
核心结论
- 新诊断RA患者在接受甲氨蝶呤起始治疗时联合短期泼尼松龙桥接,超过80%可成功停用泼尼松龙。
- 该结果支持大多数患者在短期桥接后减量至停用泼尼松龙,与EULAR推荐一致。
研究设计与样本
- 基于ARCTIC随机试验的24个月随访研究,纳入227例未使用过改善病情抗风湿药的近期起病RA患者。
- 初始治疗为甲氨蝶呤单药联合泼尼松龙桥接(7周内从15mg减至0)。
主要发现
- 7周后84%(191/227)停用泼尼松龙,3个月时89%(203/227),24个月内95%(216/227)。
- 5%(11/227)每次访视均使用泼尼松龙,2年内使用中位天数55天(IQR 48-90)。
- 7周后停用者中80%(152/191)未重新使用泼尼松龙,22%连续使用至少3个月。
关键数值与推荐
- 成功停用定义为桥接治疗后无泼尼松龙使用且后续至少4个月未使用。
- 基线平均年龄52岁(SD 13.7),平均疾病活动度评分3.47(SD 1.17),女性62%,抗CCP抗体阳性82%。
临床怎么用
- 对新诊断RA患者,可考虑甲氨蝶呤起始联合短期泼尼松龙桥接,7周内减停。
- 多数患者可成功停用激素,仅少数需延长使用,应监测连续使用≥3个月者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this paper is to examine whether patients with newly diagnosed rheumatoid arthritis (RA) can discontinue prednisolone after short-term bridging therapy. METHODS: Patients naïve to disease-modifying antirheumatic drugs with recent-onset RA in the ARCTIC (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen) trial were followed for 24 months, with initial methotrexate monotherapy and prednisolone bridging therapy (tapering doses from 15 mg to 0 over 7 weeks). We explored the proportion of patients successfully discontinuing prednisolone, defined as no prednisolone use after bridging therapy, and for at least 4 subsequent months. Discontinuation was assessed after cessation of bridging therapy at 2, 3, 6, 12, 20, and 24 months. Additionally, we examined how many patients used prednisolone continuously for ≥3 months. RESULTS: Of 230 patients, 227 started prednisolone bridging therapy and were included for analyses. At baseline, mean (SD) age was 52 (13.7) years, mean (SD) disease activity score was 3.47 (1.17), 62% patients were female, and 82% patients were anticitrullinated peptide antibody positive. After 7 weeks, 84% (191/227) had discontinued prednisolone, 89% (203/227) had discontinued at 3 months, and 95% (216/227) within 24 months. Five percent (11/227) used prednisolone at every visit. The median number of days (IQR) of prednisolone use during 2 years was 55 (48-90). Among those who discontinued after 7 weeks, 80% (152/191) did not restart prednisolone. Continuous use for at least 3 months was observed in 22%. CONCLUSIONS: In newly diagnosed patients with RA using bridging therapy when starting methotrexate, over 80% successfully discontinued prednisolone. This supports that tapering to discontinuation is achievable in most patients after short-term bridging with prednisolone, in line with current European Alliance of Associations for Rheumatology recommendations.
引用
- Brinkmann GH, Sundlisæter NP, Nordberg LB, et al. Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis. Ann Rheum Dis. 2026. PMID: 41620379. doi:10.1016/j.ard.2026.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。